A closer look at the spectrum of drug-induced liver injury in sub-Saharan Africa

References

• Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145.
   PubMed Web of Science ®Google Scholar
• Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525–2534.
   PubMed Web of Science ®Google Scholar
• Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 2014;12:159.
   PubMed Web of Science ®Google Scholar
• Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019 Jan;70(1):151–171.
   PubMedGoogle Scholar
• Gorkom V. TB control in namibia 2002-2011: progress and technical assistance. Open Infect Dis J. 2013;7:23–29.
   Google Scholar
• UNAIDS. Global AIDS update 2016. 2016.
   Google Scholar
• Escorsell A, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl. 2007;13(10):1389–1395.
   PubMed Web of Science ®Google Scholar
• Hadem J, Tacke F, Bruns T, et al. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012;10(6):664–9.e2.
   PubMed Web of Science ®Google Scholar
• Lee WM, Squires RH, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 2008;47(4):1401–1415.
   PubMed Web of Science ®Google Scholar
• Acharya SK, Panda SK, Saxena A, et al. Acute hepatic failure in India: a perspective from the East. J Gastroenterol Hepatol. 2000;15(5):473–479.
   PubMed Web of Science ®Google Scholar
• Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: A perspective from Japan. J Gastroenterol Hepatol. 2011;26(Suppl 1):65–71.
   PubMedGoogle Scholar
• Zhao P, Wang C, Liu W, et al. Causes and outcomes of acute liver failure in China. PLoS One. 2013;8(11):e80991.
   PubMed Web of Science ®Google Scholar
• Mudawi HM. Epidemiology of viral hepatitis in Sudan. Clin Exp Gastroenterol. 2008;1:9–13.
   PubMedGoogle Scholar
• Gow PJ, Jones RM, Dobson JL, et al. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol. 2004;19(2):154–159.
   PubMed Web of Science ®Google Scholar
• Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 2008;28(2):142–152.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018;84(7):1467–1477.
   PubMed Web of Science ®Google Scholar
• Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality assessment method. Expert Opin Drug Metab Toxicol. 2018;14(11):1169–1187.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14.
   PubMed Web of Science ®Google Scholar
• David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010;6:73–80.
   PubMedGoogle Scholar
• Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730–742.
   PubMedGoogle Scholar
• McGill MR, Williams CD, Xie Y, et al. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol. 2012;264(3):387–394.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis. 2002;22(2):137–144.
   PubMed Web of Science ®Google Scholar
• Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–122.
   PubMed Web of Science ®Google Scholar
• Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25, 1425 e1-3; quiz e19-20.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.
   PubMed Web of Science ®Google Scholar
• Bjornsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17(2):224.
   PubMed Web of Science ®Google Scholar
• Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139(7):876–887.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Reddy KRK, Fontana RJ, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to caucasians. Am J Gastroenterol. 2017;112(9):1382–1388.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7): 1340–1352. e7.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–455.
   PubMed Web of Science ®Google Scholar
• Bessone F, Hernandez N, Lucena M, et al. The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci. 2016;17(3):313.
   PubMed Web of Science ®Google Scholar
• Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;65(12):2007–2016.
   PubMed Web of Science ®Google Scholar
• Afum C, Astell-Burt T, Liu J, et al. Association between Aflatoxin M(1) and liver disease in HBV/HCV Infected Persons in Ghana. Int J Environ Res Public Health. 2016;13(4):377.
   PubMed Web of Science ®Google Scholar
• Ocama P, Katwere M, Piloya T, et al. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci. 2008;8(1):8–12.
   PubMed Web of Science ®Google Scholar
• Cainelli F, Vento S. Liver disease in patients with HIV in sub-Saharan Africa. Lancet HIV. 2015;2(10):e412–3.
   PubMed Web of Science ®Google Scholar
• Mouton JP, Deng D, Xiang L, et al. Adverse drug reactions causing admission to medical wards: a cross-sectional survey at 4 hospitals in South Africa. Medicine (Baltimore). 2016;95(19):e3437.
   PubMed Web of Science ®Google Scholar
• Fredy ELM. Etude des hepatites medicamenteuses dans les services de gastroenterologie de l`hopital central et du chu de yaounde (Cameroun). 2007.
   Google Scholar
• Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104–113.
   PubMed Web of Science ®Google Scholar
• WHO. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis. 2012.
   Google Scholar
• WHO. Global tuberculosis report 2018. 2018.
   Google Scholar
• Morgan DJ, Okeke IN, Laxminarayan R, et al. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011;11(9):692–701.
   PubMed Web of Science ®Google Scholar
• Auerbach BJ, Reynolds SJ, Lamorde M, et al. Traditional herbal medicine use associated with liver fibrosis in rural Rakai, Uganda. PLoS One. 2012;7(11):e41737.
   PubMed Web of Science ®Google Scholar
• Espinosa-Jovel C, Toledano R, Aledo-Serrano Á, et al. Epidemiological profile of epilepsy in low income populations. Seizure. 2018;56:67–72.
   PubMed Web of Science ®Google Scholar
• Jost J, Ratsimbazafy V, Nguyen TT, et al. Quality of antiepileptic drugs in sub-Saharan Africa: A study in Gabon, Kenya, and Madagascar. Epilepsia. 2018;59(7):1351–1361.
   PubMed Web of Science ®Google Scholar
• Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492–500.
   PubMed Web of Science ®Google Scholar
• Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52(3):1143–1155.
   PubMed Web of Science ®Google Scholar
• Sonderup MW, Wainwright H, Hall P, et al. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology. 2015;61(5):1721–1729.
   PubMed Web of Science ®Google Scholar
• Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Aids. 2009;23(13):1689–1699.
   PubMed Web of Science ®Google Scholar
• Bannister WP, Friis-Møller N, Mocroft A, et al. Incidence of abacavir hypersensitivity reactions in euroSIDA. Antivir Ther. 2008;13(5):687–696.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–732.
   PubMed Web of Science ®Google Scholar
• Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44(1 Suppl):S132–9.
   PubMedGoogle Scholar
• Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115–120.
   PubMed Web of Science ®Google Scholar
• Mataranyika PA, Kibuule D, Kalemeera F, et al. Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: findings and implications. Alexandria J Med. 2018;54(1):49–56.
   Web of Science ®Google Scholar
• Chu KM, Boulle AM, Ford N, et al. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One. 2010;5(2):e9183.
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. Aids. 2013;27(6):973–979.
   PubMed Web of Science ®Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2016.
   Google Scholar
• Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Aids. 2013;27(9):1403–1412.
   PubMed Web of Science ®Google Scholar
• Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. Aids. 2016;30(9):1483–1485.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• Wang B, Abbott L, Childs K, et al. Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. Int J STD AIDS. 2017;29(4):414–417.
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
   PubMed Web of Science ®Google Scholar
• van der Plas H, Meintjes G, Schutz C, et al. Complications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosis. PLoS One. 2013;8(2):e54145.
   PubMed Web of Science ®Google Scholar
• Bouazzi OE, Ogbu IA, Dipeolu IO. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J. 2016;25:167.
   PubMed Web of Science ®Google Scholar
• Hosford JD, von Fricken ME, Lauzardo M, et al. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2015;95(2):112–122.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166(7):916–919.
   PubMed Web of Science ®Google Scholar
• Ngouleun W, Biapa Nya PC, Pieme AC, et al. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Int J Mycobacteriol. 2016;5(4):482–488.
   PubMed Web of Science ®Google Scholar
• Bonnet M, Bhatt N, Baudin E, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis. 2013;13(4):303–312.
   PubMed Web of Science ®Google Scholar
• Jong E, Conradie F, Berhanu R, et al. Consensus statement: management of drug-induced liver injury in HIV-positive patients treated for TB. S Afr J HIV Med. 2013;14(3):113–119.
   Google Scholar
• Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Aids. 2007;21(10):1301–1308.
   PubMed Web of Science ®Google Scholar
• Naidoo S, Evans D, Jong E, et al. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. S Afr Med J. 2015;105(5):393–396.
   PubMedGoogle Scholar
• Schutz C, Ismail Z, Proxenos CJ, et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J. 2012;102(6):506–511.
   PubMed Web of Science ®Google Scholar
• Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–750.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338–347.
   PubMed Web of Science ®Google Scholar
• Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15). E3463-E3470.
   Web of Science ®Google Scholar
• Prah J, Samwel A, Ng’ang’a Z, et al. Antibiotic prescription pattern in a Ghanaian primary health care facility. Pan Afr Med J. 2017;28:214.
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Kheder S, Ali H. Prescribing rationality in Khartoum state, Sudan: an update. Sudan Med Monitor. 2014;9(2):61–66.
   Google Scholar
• Ibrahim M. Physicians’ prescribing behaviour in two tertiary health care facilities in north-western Nigeria – Analysis of 518 prescriptions. Sahel Med J. 2004;7(4):115–118.
   Google Scholar
• Chem ED, Anong DN, Akoachere JKT. Prescribing patterns and associated factors of antibiotic prescription in primary health care facilities of Kumbo East and Kumbo West Health Districts, North West Cameroon. PLoS One. 2018;13(3):e0193353.
   PubMed Web of Science ®Google Scholar
• Kalungia AC, Burger J, Godman B, et al. Non-prescription sale and dispensing of antibiotics in community pharmacies in Zambia. Expert Rev Anti Infect Ther. 2016;14(12):1215–1223.
   PubMed Web of Science ®Google Scholar
• Ba-Diop A, Marin B, Druet-Cabanac M, et al. Epidemiology, causes, and treatment of epilepsy in sub-Saharan Africa. Lancet Neurol. 2014;13(10):1029–1044.
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. Semin Liver Dis. 2014;34:145–161.
   Google Scholar
• Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly. 2010;140:w13080.
   PubMed Web of Science ®Google Scholar
• Townsend E, Hawton K, Harriss L, et al. Substances used in deliberate self-poisoning 1985-1997: trends and associations with age, gender, repetition and suicide intent. Soc Psychiatry Psychiatr Epidemiol. 2001;36(5):228–234.
   PubMed Web of Science ®Google Scholar
• Mowry JB, Spyker DA, Cantilena LR, et al. 2013 Annual Report of the American Association of Poison control centers’ national poison data system (NPDS): 31st annual report. Clin Toxicol (Phila). 2014;52(10):1032–1283.
   PubMed Web of Science ®Google Scholar
• Chandra A, Mullan P, Ho-Foster A, et al. Epidemiology of patients presenting to the emergency centre of Princess Marina Hospital in Gaborone, Botswana. Afr J Emergency Med. 2014;4(3):109–114.
   Google Scholar
• House DR, Nyabera SL, Yusi K, et al. Descriptive study of an emergency centre in Western Kenya: challenges and opportunities. Afr J Emergency Med. 2014;4(1):19–24.
   Google Scholar
• Mowry JB, Spyker DA, Brooks DE, et al. 2015 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol (Phila). 2016;54(10):924–1109.
   PubMed Web of Science ®Google Scholar
• van Hoving DJ, Hunter LD, Gerber REJ, et al. The burden of intentional self-poisoning on a district-level public Hospital in Cape Town, South Africa. Afr J Emerg Med. 2018;8(3):79–83.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis. 2014;34(2):172–193.
   PubMed Web of Science ®Google Scholar
• Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004;160(4):339–349.
   PubMed Web of Science ®Google Scholar
• Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2008;47(2):605–612.
   PubMed Web of Science ®Google Scholar
• WHO. Traditional medicine, report by the secretariat. 2013.
   Google Scholar
• Wai CT. Presentation of drug-induced liver injury in Singapore. Singapore Med J. 2006;47(2):116–120.
   PubMedGoogle Scholar
• Zhao P, Wang C, Liu W, et al. Acute liver failure associated with traditional Chinese medicine: report of 30 cases from seven tertiary hospitals in China*. Crit Care Med. 2014;42(4):e296–9.
   PubMed Web of Science ®Google Scholar
• Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol. 2008;14(45):6999–7004.
   PubMed Web of Science ®Google Scholar
• Nwokediuko SC, Osuala PC, Uduma UV, et al. Pattern of liver disease admissions in a Nigerian tertiary hospital. Niger J Clin Pract. 2013;16(3):339–342.
   PubMed Web of Science ®Google Scholar
• Mattei A, Pierre R, Didier S, et al. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol. 1995;22(5):597.
   PubMed Web of Science ®Google Scholar
• Prakash AS, Pereira TN, Reilly PE, et al. Pyrrolizidine alkaloids in human diet. Mutat Res. 1999;443(1–2):53–67.
   PubMed Web of Science ®Google Scholar
• Chen T, Mei N, Fu PP. Genotoxicity of pyrrolizidine alkaloids. J Appl Toxicol. 2010;30(3):183–196.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huo JR. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth J Med. 2010;68(6):252–260.
   PubMed Web of Science ®Google Scholar
• Yeong ML, Wakefield SJ, Ford HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. Int J Exp Pathol. 1993;74(2):211–217.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581–1588.
   PubMed Web of Science ®Google Scholar
• Program, U.A.f.I.D.b.t.S.P.S.S. Safety of medicines in Sub-Saharan Africa: assessment of pharmacovigilance systems and their performance. Arlington, VA: Management Sciences for Health.; 2011.
   Google Scholar